Geoffrey M. Parker
CIK 1491874 · CHIEF FINANCIAL OFFICER · last filed 2026-06-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.35M
Companies
9
Total Filings
131
Lifetime Open-Market Net
$5.82M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRGO | Director | 59,096 | $14.78 | $873.4K | $1.63M | 32 | 2026-06-16 |
| ALLO | CHIEF FINANCIAL OFFICER | 1,252,795 | $1.98 | $2.48M | -$95.3K | 9 | 2026-02-04 |
| Better Therapeutics, Inc. (BTTX) Delisted | Director | 1,085,138 | $0.04 | $48.4K | $917.2K | 9 | 2023-12-20 |
| CCXI | Director | 0 | $13.46 | $0 | -$2.61M | 25 | 2022-10-24 |
| Tricida, Inc. (TCDA) Delisted | COO, CFO and EVP | 118,617 | $0.11 | $12.8K | $4.25M | 17 | 2022-03-02 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 955 | — | — | $0 | 4 | 2019-06-18 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | Director | 3,851 | $18.62 | $71.7K | $58.2K | 6 | 2017-06-02 |
| Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Executive Vice President & CFO | 104,840 | $10.19 | $1.07M | $1.67M | 20 | 2015-03-23 |
| GENOPTIX INC (GXDX) Delisted | Director | 4,167 | — | — | $0 | 4 | 2011-03-01 |
Recent Filings · Page 13 of 14
131 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-06-05 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Buy (P) | +7,954 | $38.3K | EDGAR |
| 2012-03-20 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Buy (P) | +10,000 | $60.8K | EDGAR |
| 2012-03-14 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-02-13 | CCXI | Buy (P) | +4,600 | $50.5K | EDGAR |
| 2011-05-24 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Buy (P) | +10,000 | $59.5K | EDGAR |
| 2011-05-11 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Buy (P) | +20,000 | $123.4K | EDGAR |
| 2011-04-04 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-03-01 | GENOPTIX INC (GXDX) Delisted | U | −501 | -$12.5K | EDGAR |
| 2010-12-03 | GENOPTIX INC (GXDX) Delisted | Disp (D) | −166 | -$2.8K | EDGAR |
| 2010-09-03 | GENOPTIX INC (GXDX) Delisted | Disp (D) | −166 | -$2.9K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.